PLA2R1 and metabolic syndrome: Still, further studies on the interplay between anti-PLA2R antibodies, coagulation factors, and dyslipidemia will answer the question if MN subjects with positive anti-PLA2R status would benefit from more individualized anticoagulative and lipid-lowering therapies.